Issue 75, 2018

Rational design of new cyclic analogues of the antimicrobial lipopeptide tridecaptin A1

Abstract

Non-ribosomal peptides (NRPs) are a rich source of antibiotic candidates. However, it was recently discovered that resistance to NRPs can be mediated by D-stereoselective peptidases. The tridecaptins, a class of NRPs that selectively target Gram-negative bacteria, are degraded by the D-peptidase TriF. Through analysis of a solution NMR structure of tridecaptin A1, we have rationally synthesized new cyclic tridecaptin analogues that retain strong antimicrobial activity and are resistant to TriF.

Graphical abstract: Rational design of new cyclic analogues of the antimicrobial lipopeptide tridecaptin A1

Supplementary files

Article information

Article type
Communication
Submitted
17 Jul 2018
Accepted
17 Aug 2018
First published
04 Sep 2018
This article is Open Access
Creative Commons BY license

Chem. Commun., 2018,54, 10634-10637

Rational design of new cyclic analogues of the antimicrobial lipopeptide tridecaptin A1

R. D. Ballantine, Y. Li, P. Qian and S. A. Cochrane, Chem. Commun., 2018, 54, 10634 DOI: 10.1039/C8CC05790G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements